Lesson
Define the Infection Before Choosing the Drug
HAP and VAP share nosocomial ecology but occupy different timelines and delivery systems. Devices, aspiration, host reserve, hospital exposure, and prior antibiotics shape the probability of infection and resistance.
- HAP
- VAP
- Microaspiration
- Hospital ecology
- Resistance pressure
HAP begins at least 48 hours after admission.
VAP begins more than 48 hours after intubation.
Secretions and biofilm deliver organisms to distal airspaces.
Prior therapy and local flora change resistance probability.
Separate HAP from VAP
HAP begins at least 48 hours after admission and is not associated with mechanical ventilation. VAP begins more than 48 hours after endotracheal intubation.
Trace how infection reaches the lung
Microaspiration around the cuff, pooled secretions, biofilm, impaired clearance, immobility, and altered consciousness allow inoculum to reach distal airspaces.
Let local ecology change probability
Pseudomonas, other resistant gram-negative bacilli, and MRSA become more likely through prior isolation, recent antibiotic pressure, device exposure, and unit susceptibility.
Keep scope visible
The core treatment guideline addresses nonimmunocompromised adults. Profound immune compromise and opportunistic infection require a separate diagnostic and therapeutic pathway.
Quick check
Lesson
Diagnose Infection Inside Critical Illness
A new infiltrate with fever, purulent secretions, leukocyte change, or declining oxygenation supports HAP or VAP, but edema, atelectasis, ARDS, embolism, hemorrhage, aspiration pneumonitis, and drug injury can look similar.
- New infiltrate
- Clinical evidence
- VAE
- Noninfectious mimics
- Biomarker limits
Imaging, secretions, oxygenation, fever, and leukocytes form a pattern.
Edema, atelectasis, ARDS, embolism, and hemorrhage can imitate pneumonia.
A surveillance event does not establish an infectious diagnosis.
Discordant response should reopen the diagnostic model.
Require a compatible pattern
No gold standard exists. One fever, secretion change, or opacity cannot establish pneumonia by itself.
Do not equate VAE with VAP
A ventilator-associated event is a surveillance construct based on worsening ventilator support. Pneumonia causes only a portion of VAEs.
Use clinical criteria to start
The guideline recommends clinical criteria rather than PCT, CRP, sTREM-1, or CPIS as the basis for initiating therapy.
Reopen the diagnosis during failure
Fluid overload, atelectasis, pulmonary embolism, hemorrhage, ARDS, obstruction, abscess, empyema, and another infection can explain nonresponse.
Quick check
Lesson
Collect Evidence That Can Narrow Therapy
Respiratory microbiology should improve target selection, not merely generate organism names. The sample, timing, prior antibiotics, airway colonization, and result owner determine whether it can safely change therapy.
- Endotracheal aspirate
- Semiquantitative culture
- HAP specimen
- Colonization
- Result ownership
Obtain a quality sample before therapy when urgent care is not delayed.
Endotracheal semiquantitative culture is the routine approach.
Airway growth must fit burden, imaging, host response, and trajectory.
Assign the reviewer, expected time, and treatment consequence.
Use the preferred VAP approach
Noninvasive endotracheal sampling with semiquantitative culture is preferred over routine invasive quantitative sampling.
Obtain HAP respiratory culture when possible
A quality noninvasive specimen can support pathogen-directed treatment and de-escalation.
Interpret the airway, not just the report
Endotracheal tubes develop biofilm and colonization. Specimen quality, Gram stain, burden, imaging, host response, and trajectory establish clinical meaning.
Own every pending result
Document collection time, expected finalization, callback owner, susceptibility review, and the exact therapy decision the result can change.
Quick check
Lesson
Make Empiric Breadth Earn Its Place
Prompt active therapy matters most in shock and ventilatory failure, but unnecessary MRSA and dual gram-negative coverage add kidney, neurologic, hematologic, ecological, and interaction harm.
- Unit antibiogram
- Prior isolates
- Recent IV antibiotics
- Mortality risk
- Dual therapy
Individual microbiology can outweigh a broad healthcare label.
Exposure within 90 days raises resistance probability.
Shock and ventilatory failure reduce tolerance for inactive therapy.
Unit susceptibility determines whether one or two gram-negative classes are needed.
Start with current local data
Each hospital should maintain overall and unit-specific antibiograms. Unknown or poor susceptibility can justify broader initial coverage.
Retrieve individual microbiology
Prior respiratory MRSA or resistant gram-negative isolation is stronger evidence than a broad healthcare label.
Recognize recent pressure
IV antibiotics within 90 days are a major resistance signal. Drug, indication, duration, organism, and interval all matter.
Let physiology set the consequence
Septic shock and ventilatory support due to HAP increase the cost of inactive empiric therapy.
Use complementary classes
When two antipseudomonal agents are justified, choose different classes. Two beta-lactams do not provide the intended complementary strategy.
Quick check
Lesson
Construct an Executable HAP Regimen
Empiric HAP therapy covers MSSA and Pseudomonas-active gram-negative organisms. MRSA and a second antipseudomonal class are added only when patient risk, unit ecology, or mortality risk supports them.
- MSSA coverage
- Pseudomonas coverage
- MRSA gate
- Second class
- Exact exposure
Start with a locally reliable antipseudomonal backbone.
Use patient risk, unit prevalence, and mortality risk.
Add only when monotherapy reliability is not adequate.
Reassess diagnosis, exposure, cultures, and every remaining drug.
Choose the baseline agent from local data
Piperacillin-tazobactam, cefepime, ceftazidime, imipenem, meropenem, or another locally supported active agent can form the gram-negative frame.
Translate selection into an adult starting exposure
Common examples in adults with normal kidney function include piperacillin-tazobactam 4.5 g IV every 6 hours, cefepime 2 g IV every 8 hours, meropenem 1 g IV every 8 hours, or linezolid 600 mg IV every 12 hours. Vancomycin uses a loading strategy and AUC-guided maintenance under the local protocol. Renal replacement therapy, augmented clearance, allergy, infusion design, MIC, and changing organ function can require a different regimen.
Open the MRSA gate deliberately
Recent IV antibiotics, high or unknown unit MRSA prevalence, or high mortality risk can support vancomycin or linezolid.
Open the second gram-negative gate deliberately
Recent IV antibiotics, high mortality risk, structural lung disease, or low monotherapy susceptibility can justify a second class while cultures are pending.
Design the exit before the first dose
A 48 to 72 hour review should revisit diagnosis, specimen quality, susceptibility, kidney function, exposure, and whether each agent remains necessary.
Quick check
Lesson
Build VAP Therapy From the Unit Outward
VAP empiric therapy covers S. aureus, Pseudomonas, and other gram-negative bacilli. Unit susceptibility, prior antibiotics, shock, organ support, and prior isolates determine whether one or several agents are needed.
- S. aureus
- Gram-negative bacilli
- MRSA threshold
- Two-class threshold
- Toxicity reserve
Address S. aureus, Pseudomonas, and other gram-negative bacilli.
Choose vancomycin or linezolid when the evidence gate opens.
Use dual gram-negative therapy only for defined uncertainty.
Susceptibility and stability should collapse unnecessary combination therapy.
Cover the baseline VAP ecology
A locally active antipseudomonal agent provides gram-negative and often MSSA coverage.
Add MRSA therapy through evidence
Prior IV therapy or high or unknown unit MRSA prevalence supports vancomycin or linezolid.
Use two gram-negative classes conditionally
Resistance risk, more than 10 percent unit resistance to a proposed monotherapy, or unavailable susceptibility data supports a second class.
Avoid routine toxic substitutes
Aminoglycosides and colistin are not preferred empiric choices when safer active agents exist because lung exposure and organ toxicity can be unfavorable.
Narrow after the uncertainty resolves
Culture and susceptibility should convert empiric combination therapy to one targeted active agent when the patient and pathogen allow.
Quick check
Lesson
Treat Exposure as a Moving Target
Critical illness changes distribution, clearance, protein binding, tissue penetration, and extracorporeal removal. A named antibiotic is not adequate therapy unless the patient achieves an appropriate lung and plasma exposure.
- Loading dose
- Time above MIC
- Prolonged infusion
- Augmented clearance
- Measured concentrations
Reach the target promptly despite expanded volume.
Adjust repeated exposure as renal support and physiology change.
Improve beta-lactam target attainment with an operationally sound plan.
Use observed levels for true dose individualization.
Separate loading from maintenance
The initial dose answers an urgent distribution question. Maintenance answers changing clearance and repeated exposure.
Use beta-lactam PK and PD
Free time above MIC drives the minimum target. Severe or resistant infection can justify a more aggressive target under protocol.
Use prolonged infusion correctly
Extended or continuous infusion can improve target attainment but requires a loading dose, stable preparation, compatible access, and interruption plan.
Recognize high-variability phenotypes
Augmented renal clearance, hypoalbuminemia, obesity, burns, pregnancy, fluid shifts, kidney injury, RRT, and ECMO can defeat standard assumptions.
Define true dose individualization
The 2026 consensus uses measured patient beta-lactam concentrations for TDM or model-informed personalized dosing. Weight and creatinine adjustment alone are still population-based dosing.
Quick check
Lesson
Let the Organism and Mechanism Replace the Empiric Label
Definitive therapy should follow organism identity, susceptibility method, resistance mechanism, lung exposure, clinical severity, and source. Current AMR guidance changes several older fallback pathways.
- MRSA
- Pseudomonas
- ESBL Enterobacterales
- DTR Pseudomonas
- CRAB
Decide whether the recovered organism explains invasive pneumonia.
Distinguish MRSA, ESBL, DTR Pseudomonas, and CRAB pathways.
Balance susceptibility, lung exposure, toxicity, and evidence.
Recheck exposure, organ function, and microbiologic trajectory.
Select proven MRSA therapy
Use vancomycin or linezolid. Kidney function, exposure monitoring, blood counts, serotonergic therapy, bacteremia, cost, and local practice decide between them. Daptomycin is inactivated by pulmonary surfactant.
Target susceptible Pseudomonas
Use one active susceptibility-directed agent when shock and high death risk have resolved. Aminoglycoside monotherapy is not appropriate for pneumonia.
Apply the ESBL boundary
For critically ill invasive ESBL Enterobacterales disease, meropenem or imipenem is preferred. Current guidance advises against piperacillin-tazobactam or cefepime as definitive invasive ESBL therapy.
Use modern DTR Pseudomonas options
Ceftolozane-tazobactam is preferred for DTR Pseudomonas pneumonia when active. The FDA-labeled adult HABP and VABP exposure is 3 g IV every 8 hours over 1 hour for 8 to 14 days when creatinine clearance exceeds 50 mL/min, with renal adjustment and daily clearance review when function changes. Ceftazidime-avibactam and imipenem-relebactam are other preferred nonurinary options, while cefiderocol is an alternative.
Use protected sulbactam for CRAB
Sulbactam-durlobactam 1 g and 1 g IV every 6 hours is the labeled starting exposure for creatinine clearance 45 to 129 mL/min. Current guidance pairs it with imipenem or meropenem for invasive CRAB. The interval changes across renal and augmented-clearance states, and high-dose ampicillin-sulbactam combination therapy is a temporary bridge when the preferred regimen is unavailable.
Quick check
Lesson
Make Seven Days a Framework, Not an Autopilot
Seven days is standard for most improving HAP and VAP. Response, organism, complications, source control, immune state, and diagnostic certainty can justify a different course.
- Seven days
- De-escalation
- PCT boundary
- Failure
- Source control
Reassess the diagnosis, specimen, susceptibility, and clinical response.
Move to one focused agent when uncertainty resolves.
Seven days is standard for most improving HAP and VAP.
Look for exposure problems, resistance, complications, and another diagnosis.
Use the standard course
Both HAP and VAP guidelines recommend seven days for most patients, with shorter or longer treatment based on clinical, radiologic, and laboratory response.
De-escalate rather than freeze
Change broad empiric treatment to narrower therapy or monotherapy when cultures, specimen quality, trajectory, and diagnosis support it.
Keep the PCT boundary straight
PCT plus clinical criteria may assist discontinuation, but its added benefit is uncertain where routine courses already last seven days or less. PCT should not own initiation.
Investigate failure before broadening
Wrong diagnosis, inadequate exposure, resistance, abscess, empyema, obstruction, device infection, immune defect, or another source can cause nonresponse.
Stop with a complete exit
Document final indication, active days, last dose, monitoring, adverse effects, recurrence signs, follow-up owner, and prevention changes.
Quick check
Lesson
Prevent Pneumonia by Reducing Exposure and Failure
Modern prevention centers on avoiding intubation when safe, minimizing sedation, liberating from ventilation, mobilizing early, preventing aspiration, providing mechanical oral care, removing unnecessary tubes, and maintaining equipment correctly.
- Ventilator liberation
- Mobility
- Toothbrushing
- Enteral nutrition
- Equipment
Use noninvasive support when safe and appropriate.
Coordinate sedation reduction, breathing trials, and mobility.
Use daily toothbrushing without routine chlorhexidine.
Limit unnecessary tubes, circuit changes, and antimicrobial pressure.
Reduce ventilation time
Use noninvasive support when safe, multimodal sedation strategies, daily spontaneous awakening and breathing trials, and early mobility to accelerate liberation.
Position and protect the airway
Elevate the head of bed when not contraindicated, manage secretions, assess swallowing, and remove unnecessary nasogastric and endotracheal tubes.
Update oral care
Provide daily toothbrushing without routine chlorhexidine. The 2022 update found unclear VAP benefit and a possible mortality signal with chlorhexidine.
Feed and maintain deliberately
Use early enteral rather than parenteral nutrition when safe. Change ventilator circuits only when visibly soiled or malfunctioning.
Prevent nonventilator HAP too
Hand hygiene, mobility, oral care, dysphagia and aspiration assessment, pulmonary hygiene, vaccination, and stewardship extend prevention beyond the ICU.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 174 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- ATS and IDSA HAP and VAP Guideline
- SHEA, IDSA, APIC, AHA, and Joint Commission Prevention Update
- IDSA 2026 Resistant Gram-Negative Guidance
- 2026 Beta-Lactam Dose Individualization Consensus
- Surviving Sepsis Campaign 2026
- FDA HABP and VABP Drug Development Guidance
- FDA ZERBAXA Prescribing Information
- FDA XACDURO Integrated Review